Skip to main content
. 2019 Nov 20;25(3):e469–e476. doi: 10.1634/theoncologist.2019-0541

Table 3.

Comparison of the median time to treatment failure and disease control rate between patients with metastatic colorectal cancer in the T‐B group and the T group

Effect T‐B group (n = 21) T group (n = 36) p value
Time to treatment failure, median (95% CI), months 5.6 (3.4–NA)a 2.1 (1.8–3.2)a <.001a
Tumor response rate, %
Response rate (CR + PR) 0 (0/21) 0 (0/36) 1.000b
Disease control rate (CR + PR + SD) 76.1 (16/21) 25.0 (9/36) .001b
1‐year survival, % 33.3 (7/21) 11.1 (4/36) .078b

graphic file with name ONCO-25-e469-g006.jpg

Data indicate median with 25th and 75th percentiles or number.

a

Data were statistically analyzed using the log rank test.

b

Data were statistically analyzed using Fisher's exact probability test.

Abbreviations: CI, confidence interval; CR, complete response; NA, not applicable because calculation was impossible; PR, partial response; SD, stable disease; T group, patients receiving TAS‐102 monotherapy; T‐B group, patients receiving TAS‐102 plus bevacizumab.